Influenza b
Pro Research Analysisby 
Searched over 200M research papers for "influenza b"
Influenza B: Epidemiology, Clinical Impact, and Vaccine Development
Epidemiology of Influenza B in the Asia-Pacific Region
Influenza B is a significant cause of morbidity across the Asia-Pacific region, affecting all age groups, with a higher incidence in children aged 1 to 10 years . The virus circulates in two main lineages, Yamagata and Victoria, which often co-circulate during the influenza season. However, mismatches between the vaccine B lineage and the circulating lineage are common, suggesting a potential benefit from shifting from trivalent to quadrivalent vaccines to provide broader protection .
Clinical Characteristics and Disease Burden
The clinical presentation of influenza B is similar to that of influenza A, though some studies report conflicting findings . Influenza B can cause severe illness and has been associated with higher hospitalization rates and mortality, particularly in children and high-risk groups Sharma2019Zaraket2020Tran2016. For instance, during the 2010-2011 flu season, influenza B was responsible for 38% of pediatric deaths despite only accounting for 26% of circulating strains . Additionally, children hospitalized with influenza B often present with symptoms such as fever, rhinorrhea, and cough, and may develop severe complications like pneumonia and respiratory failure Liou1987Baine1980.
Vaccine Development and Efficacy
Recent advancements in vaccine development, including the use of reverse genetics, have improved the efficacy of influenza B vaccines. The inclusion of both Yamagata and Victoria lineages in quadrivalent vaccines has enhanced protection, although these vaccines are not yet universally available . Studies have also identified broadly neutralizing antibodies that protect against both lineages of influenza B, offering hope for the development of a universal flu vaccine .
Economic and Clinical Management Considerations
The economic burden of influenza B is significant, with limited data on hospitalization rates and length of stay highlighting the need for better reporting and understanding of the disease's impact . Neuraminidase inhibitors (NAIs) and the new polymerase inhibitor baloxavir have shown efficacy in treating influenza B, particularly in high-risk patients . Effective clinical management strategies are crucial, especially for children and those with underlying health conditions, to mitigate the severe outcomes associated with influenza B infections Zaraket2020Tran2016.
Conclusion
Influenza B is a critical public health concern with substantial morbidity and mortality, particularly among children and high-risk populations. Improved vaccine formulations and better clinical management strategies are essential to reduce the disease burden. Continued research and surveillance are necessary to enhance our understanding and control of influenza B.
Sources and full results
Most relevant research papers on this topic